Sasanlimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Sasanlimab
- anti pd 1 checkpoint inhibitor pf 06801591
- ANTI-PD-1 CHECKPOINT INHIBITOR PF-06801591
- pf 06801591
- PF-06801591
- rn 888
- RN-888
- sasanlimab
- Sasanlimab
- sasanlimab [INN]
- SASANLIMAB [USAN]
- Sasanlimab [WHO-DD]
- sasanlimab inn
- sasanlimab usan
- sasanlimab who dd
- ATC classification codes
- L01FF
- CAS registry numbers
- 2206792-50-7
- ChEMBL ID
- CHEMBL4298191
- FDA ingredient codes (UNII)
- LZZ0IC2EWP
- Status
- application_withdrawn
- Approved indications
- Treatment of bladder cancer in adults indicated for the treatment of adult indicated for treatement of bladder cancer.
- Product number
- EMEA/H/C/006641
- Authorisation holder
- Pfizer Europe MA EEIG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Urinary Bladder Neoplasms
European medicines record
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Protein identifier
- Q15116
Open Targets mechanisms
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Neoplasm Metastasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009708
- Subject identifier
- D009362
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 1
- Condition identifier
- EFO_0008528
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009708
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002367
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004647
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004987
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005089
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005097
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005611
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005627
- Highest recorded phase
- 1
And 12 more, listed on the interactive page.
- NCT02616185
- NCT04165317
- NCT05259397
- NCT04458259
- NCT04585815
- NCT06218069
- NCT05241340
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain: anti-VEGFA
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Glycosylation sites (N)
- Sequence
- Asn-294 $ Asn-294''''
- Component
- Light chain: anti-VEGFA
- Type
- Protein
- Sequence
- DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-94' $ 23'''-94''' $ 131-220' $ 131''-220''' $ 140'-200' $ 140'''-200''' $ 144-200 $ 144''-200'' $ 223-223'' $ 226-226'' $ 258-318 $ 258''-318'' $ 364-422 $ 364''-422''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-294 $ Asn-294''
Related records
Trials (25)
- A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
- A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
- A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
- A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
- A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
- Ketohexokinase Inhibition in Hereditary Fructose Intolerance
- Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
- PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
In development for (6)
- Neoplasm Phase 1
- Non-Hodgkin lymphoma Phase 1
- Non-small cell lung carcinoma Phase 2
- Prostate adenocarcinoma Phase 1
- Urinary bladder cancer Phase 3
- Urothelial carcinoma Phase 3
Targets (1)
- PDCD1 Programmed cell death protein 1 antagonist